June 21, 2023
Novo Japan President Kasper Bødker Mejlvang The Japan launch of Novo Nordisk’s Wegovy (semaglutide), approved earlier this year as the country’s first obesity drug in three decades, is being pushed back as the company sees “unprecedented demand” globally, local president...read more